139 related articles for article (PubMed ID: 26572968)
1. Effects of Mutations on the Reconfiguration Rate of α-Synuclein.
Acharya S; Saha S; Ahmad B; Lapidus LJ
J Phys Chem B; 2015 Dec; 119(50):15443-50. PubMed ID: 26572968
[TBL] [Abstract][Full Text] [Related]
2. Aggregation of α-synuclein is kinetically controlled by intramolecular diffusion.
Ahmad B; Chen Y; Lapidus LJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2336-41. PubMed ID: 22308332
[TBL] [Abstract][Full Text] [Related]
3. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Rutherford NJ; Moore BD; Golde TE; Giasson BI
J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for preventing α-synuclein aggregation by a molecular tweezer.
Acharya S; Safaie BM; Wongkongkathep P; Ivanova MI; Attar A; Klärner FG; Schrader T; Loo JA; Bitan G; Lapidus LJ
J Biol Chem; 2014 Apr; 289(15):10727-10737. PubMed ID: 24567327
[TBL] [Abstract][Full Text] [Related]
6. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
8. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
9. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.
Ahmad B; Lapidus LJ
J Biol Chem; 2012 Mar; 287(12):9193-9. PubMed ID: 22267729
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein aggregation variable temperature and variable pH kinetic data: a re-analysis using the Finke-Watzky 2-step model of nucleation and autocatalytic growth.
Morris AM; Finke RG
Biophys Chem; 2009 Mar; 140(1-3):9-15. PubMed ID: 19101068
[TBL] [Abstract][Full Text] [Related]
11. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
12. Long-range correlated dynamics in intrinsically disordered proteins.
Parigi G; Rezaei-Ghaleh N; Giachetti A; Becker S; Fernandez C; Blackledge M; Griesinger C; Zweckstetter M; Luchinat C
J Am Chem Soc; 2014 Nov; 136(46):16201-9. PubMed ID: 25331250
[TBL] [Abstract][Full Text] [Related]
13. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
14. The aggregation and fibrillation of alpha-synuclein.
Fink AL
Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679
[TBL] [Abstract][Full Text] [Related]
15. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Deleersnijder A; Gerard M; Debyser Z; Baekelandt V
Trends Mol Med; 2013 Jun; 19(6):368-77. PubMed ID: 23648364
[TBL] [Abstract][Full Text] [Related]
16. Function of α-synuclein and PINK1 in Lewy body dementia (Review).
Minami A; Nakanishi A; Matsuda S; Kitagishi Y; Ogura Y
Int J Mol Med; 2015 Jan; 35(1):3-9. PubMed ID: 25355138
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
18. The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity.
Plotegher N; Kumar D; Tessari I; Brucale M; Munari F; Tosatto L; Belluzzi E; Greggio E; Bisaglia M; Capaldi S; Aioanei D; Mammi S; Monaco HL; Samo B; Bubacco L
Hum Mol Genet; 2014 Nov; 23(21):5615-29. PubMed ID: 24895406
[TBL] [Abstract][Full Text] [Related]
19. Interactions between metals and alpha-synuclein--function or artefact?
Brown DR
FEBS J; 2007 Aug; 274(15):3766-74. PubMed ID: 17617226
[TBL] [Abstract][Full Text] [Related]
20. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.
Ghosh D; Sahay S; Ranjan P; Salot S; Mohite GM; Singh PK; Dwivedi S; Carvalho E; Banerjee R; Kumar A; Maji SK
Biochemistry; 2014 Oct; 53(41):6419-21. PubMed ID: 25268550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
